| abstract |
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier, and a therapeutically effective amount of androst-5-ene-3??,17??-diol or a prodrug thereof in combination with at least one active ingredient selected from the group consisting of dehydrocpiandrosterone, dehydroepiandrosterone-sulfate, and estrogen, wherein any prodrug is an ester or ether prodrug of androst-5-ene-3??,17??-diol which is pharmacologically inactive and which is enzymatically or spontaneously converted in vivo into androst-5-ene-3??,17??-diol, and wherein said pharmaceutical composition is used to treat or reduce the likelihood of acquiring any of the conditions selected from the group consisting of reduced or imbalanced concentrations of sex steroids, symptoms of menopause, vaginal atrophy, hypogonadism, osteoporosis, diminished libido, skin atrophy, skin dryness, urinary incontinence, obesity, cardiovascular disease, atherosclerosis, insulin resistance, loss of memory, and Alzheimers disease. |